Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules

Core Points - Enzo Biochem, Inc. has been notified by the NYSE of non-compliance with listing standards due to market capitalization and stockholder's equity being below $50 million, and average closing stock price being below $1.00 [1][3] - The company has 18 months to address market capitalization and stockholder's equity deficiencies, and 6 months to address the average closing stock price deficiency [1][2] - Enzo Biochem plans to submit a compliance plan to the NYSE by February 21, 2025, to rectify the identified deficiencies [3] Company Overview - Enzo Biochem has been operating as a life sciences company for over 45 years, primarily through its Life Sciences division, Enzo Life Sciences [5] - The company focuses on labeling and detection technologies, offering a comprehensive portfolio of products including antibodies, genomic probes, assays, biochemicals, and proteins [5] - Enzo Biochem monetizes its technology through global distribution and licensing [5]